Publicação científica trimestral do CREMERJ - volume 2 - número 3 - 2023

60 Vacinação no idoso Ronaldo Rozenbaum Med. Ciên. e Arte , Rio de Janeiro, v.2, n.3, p.38-60, jul-set 2023 59. COVID-19 Cumulative Infection Collaborators Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet. 2022;399(10344):2351. Epub 2022 Apr 8. 60. https://www.cdc.gov/vaccines/vpd/rsv/public/older-adults.html 61. Papi A, Ison MG, Langley JM, et al.; AReSVi-006 Study Group. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med 2023; 388:595-608. DOI: https://www.nejm.org/doi/10.1056/ NEJMoa2209604. PMID:36791160. 62. Walsh EE, Pérez Marc G, Zareba AM, et al.; RENOIR Clinical Trial Group. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023; 388:1465–77. DOI: https://www. nejm.org/doi/10.1056/NEJMoa2213836. PMID:37018468. 63. Melgar M, Britton A, Roper LE, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices —United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:793–801. DOI: http://dx.doi.org/10.15585/mmwr.mm7229a4.